Genetic Susceptibility and Infectious Triggers in autoimmune diseases: The role of SARS-CoV-2
DOI:
https://doi.org/10.33448/rsd-v14i8.49396Keywords:
Autoimmune diseases, Genetic factors, Infections, SARS-CoV-2.Abstract
The immune system operates through multiple mechanisms, not only to protect against foreign agents but also to combat neoplasms and graft rejection. Additionally, it employs selective self-tolerance mechanisms to prevent attacks on the body's own antigens. Dysregulation of these mechanisms, which can result from genetic alterations and/or the activity of infection-causing agents, culminates in the development of autoimmune diseases (AD). Genetic defects, such as changes in the genes responsible for the major histocompatibility complex (MHC) and polymorphisms, may contribute to the etiology of these diseases. Furthermore, bacteria and viruses can influence the pathophysiology of these diseases by inducing intense inflammation that leads to endothelial damage or stimulates the expression of autoantibodies, as observed during SARS-CoV-2 infection. Specifically, the virus responsible for Covid-19 may exacerbate the prognosis of patients with pre-existing autoimmune diseases and contribute to their chronicity. In this context, the aim of this study is to conduct a systematic literature review on genetic factors and the role of infections in the development of autoimmune diseases.
References
Alzabin, S., & Venables, P. J. (2012). Etiology of autoimmune disease: Past, present and future. Expert Review of Clinical Immunology, 8(2), 111-113. https://doi.org/10.1586/eci.11.88
Bigley, T. M., & Cooper, M. A. (2021). Monogenic autoimmunity and infectious diseases: The double-edged sword of immune dysregulation. Current Opinion in Immunology, 72, 230-238. https://doi.org/10.1016/j.coi.2021.06.013
Booth, A., Sutton, A., Papaioannou, D. (2016). Systematic approaches to a successful literature review. Sage Publications.
Boussier, J., et al. (2022). Severe COVID-19 is associated with hyperactivation of the alternative complement pathway. Journal of Allergy and Clinical Immunology, 149(2), 550-556.e2. https://doi.org/10.1016/j.jaci.2021.11.004
Bruserud, Ø., et al. (2016). AIRE-mutations and autoimmune disease. Current Opinion in Immunology, 43, 8-15. https://doi.org/10.1016/j.coi.2016.07.003
Costa, A. L. P., Silva-Júnior, A. C. S., & Pinheiro, A. L. (2019). Fatores associados a etiologia e patogênese das doenças autoimunes. Arquivos Catarinenses de Medicina, 48(2), 92-106.
Deng, Q., et al. (2019). The emerging epigenetic role of CD8+T cells in autoimmune diseases: A systematic review. Frontiers in Immunology, 10, 856. https://doi.org/10.3389/fimmu.2019.00856
Fousteri, G., & Jhatakia, A. D. (2019). Viral infections and autoimmune disease: Roles of LCMV in delineating mechanisms of immune tolerance. Viruses, 11(10), 885. https://doi.org/10.3390/v11100885
Freire-de-Lima, L., et al. (2021). Autoimmune disorders & COVID-19. Medicines, 8(10), 55. https://doi.org/10.3390/medicines8100055
Gough, D., Oliver, S., Thomas, J. (2017). An introduction to systematic reviews. Sage Publications.
Gracia-Ramos, A. E., & Saavedra-Salinas, M. Á. (2021). Can the SARS-CoV-2 infection trigger systemic lupus erythematosus? A case-based review. Rheumatology International, 41(4), 799-809. https://doi.org/10.1007/s00296-021-04794-7
Halpert, G., & Shoenfeld, Y. (2020). SARS-CoV-2, the autoimmune virus. Autoimmunity Reviews, 19(12), 102695. https://doi.org/10.1016/j.autrev.2020.102695
Higgins, J. P. T., Thomas, J., Chandler, J., et al. (Eds.). (2022). Cochrane Handbook for Systematic Reviews of Interventions (version 6.3). Cochrane. https://training.cochrane.org/handbook
Hoshino, K., et al. (2010). Anti-MDA5 and anti-TIF1-γ antibodies have clinical significance for patients with dermatomyositis. Rheumatology, 49(9), 1726-1733. https://doi.org/10.1093/rheumatology/keq153
Karaderi, T., et al. (2020). Host genetics at the intersection of autoimmunity and COVID-19: A potential key for heterogeneous COVID-19 severity. Frontiers in Immunology, 11, 586111. https://doi.org/10.3389/fimmu.2020.586111
Karami Fath, M., et al. (2021). SARS-CoV-2 proteome harbors peptides which are able to trigger autoimmunity responses: Implications for infection, vaccination, and population coverage. Frontiers in Immunology, 12, 705772. https://doi.org/10.3389/fimmu.2021.705772
Kato, H., et al. (2006). Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature, 441(7089), 101-105. https://doi.org/10.1038/nature04734
Knight, J. S., et al. (2021). The intersection of COVID-19 and autoimmunity. Journal of Clinical Investigation, 131(24), 154886. https://doi.org/10.1172/jci154886
Kos, I., et al. (2021). Increased B-cell activity with consumption of activated monocytes in severe COVID-19 patients. European Journal of Immunology, 51(6), 1449-1460. https://doi.org/10.1002/eji.202049163
Kumar, P., et al. (2019). Restoring self-tolerance in autoimmune diseases by enhancing regulatory T-cells. Cellular Immunology, 339, 41-49. https://doi.org/10.1016/j.cellimm.2018.09.008
Lin, X., & Lu, L. (2020). B cell-mediated autoimmune diseases. Advances in Experimental Medicine and Biology, 145-160. https://doi.org/10.1007/978-981-15-3532-1_11
Littera, R., et al. (2020). Human leukocyte antigen complex and other immunogenetic and clinical factors influence susceptibility or protection to SARS-CoV-2 infection and severity of the disease course: The Sardinian experience. Frontiers in Immunology, 11, 605688. https://doi.org/10.3389/fimmu.2020.605688
Lorenz, M. H., & Herrmann, J. R. (2001). The pathogenesis of autoimmune diseases. Scandinavian Journal of Clinical and Laboratory Investigation, 61(235), 16-26. https://doi.org/10.1080/003655101753352004
Malik, Y. S., et al. (2020). Emerging novel coronavirus (2019-NCoV) - Current scenario, evolutionary perspective based on genome analysis and recent developments. Veterinary Quarterly, 1-12. https://doi.org/10.1080/01652176.2020.1727993
Mitratza, M., et al. (2020). Systemic autoimmune disease as a cause of death: Mortality burden and comorbidities. Rheumatology, 60(3), 1321-1330. https://doi.org/10.1093/rheumatology/keaa537
Mobasheri, L., et al. (2022). SARS-CoV-2 triggering autoimmune diseases. Cytokine, 154, 155873. https://doi.org/10.1016/j.cyto.2022.155873
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G. (2009). Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Medicine, 6(7), e1000097. https://doi.org/10.1371/journal.pmed.1000097
Murimi, I. B., et al. (2020). Health care utilization and costs of systemic lupus erythematosus by disease severity in the United States. The Journal of Rheumatology, 47(7), 999-1007. https://doi.org/10.3899/jrheum.191187
Murugan, A. K., & Alzahrani, A. S. (2021). SARS-CoV-2 plays a pivotal role in inducing hyperthyroidism of Graves' disease. Endocrine, 73(2), 243-254. https://doi.org/10.1007/s12020-021-02770-6
Nunez-Castilla, J., et al. (2022). Potential autoimmunity resulting from molecular mimicry between SARS-CoV-2 spike and human proteins. Viruses, 14(7), 1415. https://doi.org/10.3390/v14071415
Oglesby, A., et al. (2014). Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. Applied Health Economics and Health Policy, 12(2), 179-190. https://doi.org/10.1007/s40258-014-0085-x
Omarjee, L., et al. (2020). Immunometabolism at the cornerstone of inflammaging, immunosenescence, and autoimmunity in COVID-19. Aging. https://doi.org/10.18632/aging.202422
Opdenakker, G., & Van Damme, J. (2021). Interferons and other cytokines, genetics and beyond in COVID-19 and autoimmunity. Cytokine & Growth Factor Reviews, 58, 134-140. https://doi.org/10.1016/j.cytogfr.2021.01.004
Page, M. J., McKenzie, J. E., Bossuyt, P. M., et al. (2021). The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ, 372, n71. https://doi.org/10.1136/bmj.n71
Pereira, A. S. et al. (2018). Metodologia da pesquisa científica. [free ebook]. Santa Maria: Editora da UFSM.
Rivera, E. G., et al. (2022). SARS-CoV-2/COVID-19 and its relationship with NOD2 and ubiquitination. Clinical Immunology, 238, 109027. https://doi.org/10.1016/j.clim.2022.109027
Sacchi, M. C., et al. (2021). SARS-CoV-2 infection as a trigger of autoimmune response. Clinical and Translational Science, 14(3), 898-907. https://doi.org/10.111
Sollid, L. M., et al. (2014). Molecular mechanisms for contribution of MHC molecules to autoimmune diseases. Current Opinion in Immunology, 31, 24-30. https://doi.org/10.1016/j.coi.2014.08.005
Thomas, J., Brunton, J., Graziosi, S. (2017). EPPI-Reviewer 4: Software for research synthesis. EPPI-Centre Software.
Wang, L., et al. (2015). Human autoimmune diseases: A comprehensive update. Journal of Internal Medicine, 278(4), 369-395. https://doi.org/10.1111/joim.12395
Wong, C. K., et al. (2004). Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome. Clinical & Experimental Immunology, 136(1), 95-103. https://doi.org/10.1111/j.1365-2249.2004.02415.x
Yoshikawa, T., et al. (2008). Severe acute respiratory syndrome (SARS) coronavirus-induced lung epithelial cytokines exacerbate SARS pathogenesis by modulating intrinsic functions of monocyte-derived macrophages and dendritic cells. Journal of Virology, 83(7), 3039-3048. https://doi.org/10.1128/jvi.01792-08
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Isabela Santos Cisterna, Lyon Alves Balduino, Lucilla Ribeiro Ávila, João Gabriel Moreira Arantes, Brenda Carneiro de Moura, Bárbara Rodrigues Garcia
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
